Navigation Links
New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients
Date:5/15/2008

>Colorectal cancer

-- Avastin: The first presentation of data from Avastin-based therapy with

or without cetuximab (a drug which attacks cancer differently to

Avastin) in patients with metastatic colorectal cancer will be shared.

-- Avastin: Impressive long-term overall survival data at two years,

involving some 4,000 patients treated with Avastin first-line in

combination with a variety of chemotherapy regimens will confirm the

pivotal role that Avastin is now playing in patients with advanced

colorectal cancer. The results of the studies are significant because

over 50 percent of people diagnosed with colorectal cancer currently

die of the disease and these data show that improvements in survival

are achievable. (1)

Roche will present nearly 300 abstracts and posters at ASCO that demonstrate advances in other major cancers, as well as the data already described above in breast and colorectal. With one of the most comprehensive oncology research and development pipelines in the industry, Roche is striving to deliver even more treatment options in the fight against cancer. For example, Avastin's clinical trial program includes 40,000 patients worldwide.

Key sessions at which Roche data will be presented include:

Breast cancer

Avastin AVADO study. Miles D, et al, Sunday 1 June 2008,

Abstract No. LBA1011, oral 8:30am - 8:45am, E

presentation Hall D1

ASCO press briefing Saturday 31 May

2008, 9:00am, Press

Centre

Herceptin HER2-positive metastatic breast Tuesday 3 June 2008,

cancer study. Minckwitz G Von, et 8:00am - 12:00pm,

al, Abstract No. 1025, Poster No.
'/>"/>

SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
2. Researchers Identify Virus Possibly Responsible for Declining Honeybee Population Using 454 Sequencing Technology from Roche
3. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
4. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
5. Roche Announces Positive Results in Solid Tumors Using Human Monoclonal Antibody Against IGF-1R (R1507)
6. Roche Diagnostics HIV Viral Load Test Used in Clinical Trials for Isentress, a New Class of HIV Drug
7. Roches Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
8. Two Pivotal Phase III Studies for Roches ACTEMRA(TM) (tocilizumab) Demonstrate Significant Improvement in Rheumatoid Arthritis Symptoms
9. Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
10. Roche responds to announcement of IDEAL hepatitis C trial results
11. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... Boston Scientific Corporation (NYSE: BSX ... Suisse Annual Healthcare Conference on Tuesday, November 11, 2014 ... Brennan , executive vice president and chief financial officer, ... approximately 8:00 a.m. PT followed by a question and ... presentation and question and answer session will be available ...
(Date:10/30/2014)... NEW YORK , Oct. 30, 2014  The ... United States is growing steadily, thanks to ... years, as a result of the economic downturn, retail ... was a year of opportunities, as the number of ... market researcher,s report, Retail Clinics Market Overview and ...
(Date:10/30/2014)... United Kingdom , Oct. 30, 2014 ... (Nasdaq: CBRX ) and Maryland ... drug developers with improved efficiency during clinical development that ... Diego next week. This partnership ... technologies platform, which it launched earlier this month. The ...
Breaking Medicine Technology:Boston Scientific To Participate In 2014 Credit Suisse Annual Healthcare Conference 2Report: Drugstore Chains Drive Retail Clinic Growth 2Report: Drugstore Chains Drive Retail Clinic Growth 3Molecular Profiles To Launch US Strategic Alliance At AAPS 2Molecular Profiles To Launch US Strategic Alliance At AAPS 3
... HIGHLIGHTS:2011 Results (all percentages are to comparable periods ... increased 11% to $626 million. Q3 sales grew organically by ... organically by 4% and 2%, respectively.  Recently completed acquisitions contributed ... contributed an additional 5% to reported sales growth in Q3. ...
... Oct. 25, 2011 Abbott (NYSE: ABT ... – one undergraduate and one graduate – living with ... Undergraduate Student Scholarship, and Emily Kramer-Golinkoff, winner of the ... with CF who were eligible to receive the two ...
Cached Medicine Technology:Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 2Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 3Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 4Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 5Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 6Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 7Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 8Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 9Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 10Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 11Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 12Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 13Abbott Awards CFCareForward Scholarships to Two Students Living With Cystic Fibrosis Pursuing Undergraduate and Graduate Degrees 2Abbott Awards CFCareForward Scholarships to Two Students Living With Cystic Fibrosis Pursuing Undergraduate and Graduate Degrees 3
(Date:10/30/2014)... Lauderdale, FL (PRWEB) October 30, 2014 ... US Joint Commission Accredited teleradiology and specialty telemedicine ... that in addition to its existing teleradiology services ... multispecialty second opinion and expert telemedicine services, to ... Texas. , As a result of this innovative ...
(Date:10/30/2014)... The annual meeting of The North ... on Saturday, October 18th, marking the end of the ... NAMS is North America’s leading non-profit organization dedicated to ... women during midlife and beyond through an understanding of ... thought leaders from fields as varied as gynecology, sociology, ...
(Date:10/30/2014)... When it comes to heart disease, a new study finds ... they have symptoms that spell trouble. "The main danger ... more severe or advanced stage of heart disease, there are ... Fulbright Scholar and research fellow at the Harvard School of ... and Stroke Foundation of Canada. In the study, researchers ...
(Date:10/30/2014)... HealthDay Reporter WEDNESDAY, Oct. 29, 2014 (HealthDay ... your health, a new study reports. Previous research has ... and prevent osteoporosis. These benefits to bone health have led ... healthy diet. But this new study found that drinking ... from bone fractures, and was linked to an overall higher ...
(Date:10/30/2014)... 29, 2014 (HealthDay News) -- Americans, opinions about the ... a new study finds. Democratic voters are strongly ... to the researchers. Almost three-quarters of Democrats want the ... percent want Congress to implement the current law, while ... ACA. Among Independent voters, one-third want the law ...
Breaking Medicine News(10 mins):Health News:USARAD HOLDINGS INC, SECONDOPINIONS.COM® Pioneers Specialty On-Demand Telemedicine And Second Opinion Service At Houston-Based, Mission Bend Freestanding ER Chain 2Health News:USARAD HOLDINGS INC, SECONDOPINIONS.COM® Pioneers Specialty On-Demand Telemedicine And Second Opinion Service At Houston-Based, Mission Bend Freestanding ER Chain 3Health News:Highlights from The North American Menopause Society 25th Annual Meeting 2Health News:Highlights from The North American Menopause Society 25th Annual Meeting 3Health News:Women Often Ignore Signs of Heart Trouble 2Health News:Is Milk Your Friend or Foe? 2Health News:Is Milk Your Friend or Foe? 3Health News:Voters' Views on Obamacare Split Along Party Lines 2
... , , HARRISBURG, Pa., July 24 ... air quality partnerships have forecast an air quality action day for ... and Liberty/Clairton, regions. , , Due ... predicts Thursday will be code ORANGE for elevated ozone levels. ...
... , , PORTLAND, Ore., July 24 ... first and only FDA-approved microsphere-enhanced collagen filler for the correction of smile ... years due to its proven success and effectiveness for the long lasting ... Vu commented, "Artefill is a great product for many reasons. First ...
... , , , ALBANY, ... Transportation announced that tomorrow, July 25, will be an Air ... unhealthy, especially for sensitive individuals, such as children, seniors and ... high levels of ground-level ozone pollution. The alert is issued ...
... , WASHINGTON, July 24 VistA Imaging, the medical ... (VA) medical centers, attained over one billion stored images in January ... , "Using this technology, VA has established an ... immediate access to patient records regardless of their location," said Dr. ...
... , , , SAN ... G. Komen for the Cure, one of over 100 Affiliates nationwide dedicated ... over $1.6 million dollars to support Bay Area breast health education and ... The Komen San Francisco Bay Area Affiliate,s local fundraising ...
... at The University of Texas Health Science Center at Houston ... key to what causes colic, inconsolable crying in an otherwise ... just about anything that comes through the door," said J. ... Texas Medical School at Houston, which is part of the ...
Cached Medicine News:Health News:Air Quality Action Day Forecast for Thursday in All Regions of Pennsylvania 2Health News:Dr. Kim-Chi Vu in Portland Selects Artefill to Meet Growing Patient Demand for a Longer Lasting Dermal Filler 2Health News:Dr. Kim-Chi Vu in Portland Selects Artefill to Meet Growing Patient Demand for a Longer Lasting Dermal Filler 3Health News:Air Quality Action Day Declared for Saturday, July 25, 2009 2Health News:VA Medical Imaging Reaches Record Level 2Health News:San Francisco Bay Area Affiliate of the Susan G. Komen for the Cure Funds Over $1.6 Million This Year to Community Outreach Programs 2Health News:San Francisco Bay Area Affiliate of the Susan G. Komen for the Cure Funds Over $1.6 Million This Year to Community Outreach Programs 3Health News:San Francisco Bay Area Affiliate of the Susan G. Komen for the Cure Funds Over $1.6 Million This Year to Community Outreach Programs 4Health News:Pinpointing cause of colic: UT Houston researchers identify organism 2
... Cronin, Inc. is a ... Footwear, Orthopedic Softgoods, and ... Our products are of ... available in the USA ...
... lightweight brace is designed for the ... fractures. The anatomically correct design achieves ... for optimal control of ulnar segments. ... motion is permitted to prevent problems ...
Finger /Thumb Splint has a stay that may be shaped to hold finger or thumb in exact degree of flexion. It also has a contact closure....
... joint or DIP joint flexioncontractures of any degree. ... gel-lining cushions injured fingers so treatment to straighten ... more successful therapy results. Use during the day ... maintain gains in motion. Available in small, medium ...
Medicine Products: